Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma - PubMed
4 hours ago
- #immunotherapy
- #oncology
- #hematology
- Study assessed real-world effectiveness and safety of lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell lymphoma (LBCL) patients.
- Included high-risk patients, those with secondary central nervous system (sCNS) involvement, comorbidities, and poor fitness.
- Data from 1116 patients showed median age of 71.1 years, with 72.3% aged ≥65 years.
- Objective response rate was 81.2%, and complete response rate was 71.3%.
- 12-month duration of response, progression-free survival, and overall survival rates were 60.2%, 51.2%, and 67.6%, respectively.
- Cytokine release syndrome reported in 51.0% of patients, with grade ≥3 events in 2.5%.
- Immune effector cell-associated neurotoxicity syndrome reported in 26.6% of patients, with grade ≥3 events in 9.2%.
- 12-month nonrelapse mortality rate was 6.1%.
- Findings reinforce liso-cel's effectiveness and safety in a broad R/R LBCL population.